Spectral Medical (TSE:EDT) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Spectral Medical is pushing forward with its Tigris trial, enrolling 136 patients by the end of November despite supply chain disruptions caused by Hurricane Helene. The company expects to achieve full enrollment by the end of Q1 2025 and remains optimistic about overcoming these temporary setbacks.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.